B
Baton Rouge Vascular Access
Us-based company operating in the healthcare sector
About Baton Rouge Vascular Access
Baton Rouge Vascular Access operates as a specialized outpatient center providing minimally invasive vascular care, primarily serving the community of Baton Rouge, Louisiana since 2002. The facility is part of Azura Vascular Care, a national network of ambulatory surgery centers that was rebranded from Fresenius Vascular Care in June 2017. This network is a division of Fresenius Medical Care North America, a major provider of renal and chronic condition care. The strategic rebranding to Azura Vascular Care was initiated to unify over 65 centers under a single brand, reflecting a broader scope of services beyond its original renal focus and enhancing national brand awareness.
The business model centers on providing cost-effective vascular treatments in a comfortable outpatient setting, serving as an alternative to hospital-based procedures. Azura Vascular Care operates through various business models, including joint ventures with physicians, managing ambulatory surgery centers, and acting as extensions of physician practices. This structure is designed to offer entrepreneurial physicians a collaborative platform while maintaining clinical autonomy. The parent company, Fresenius Medical Care North America, has a history of strategic acquisitions to expand its vascular care services, including the acquisition of National Vascular Care in 2010 and American Access Care Holdings in 2011.
Baton Rouge Vascular Access specializes in dialysis access management for patients with end-stage renal disease (ESRD) and the treatment of peripheral artery disease (PAD). The center provides procedures such as fistulagrams, thrombectomies, and catheter insertions and removals. The medical team includes interventional nephrologists and vascular surgeons, such as Dr. Christopher Peter Luscy and Dr. Wajeeh Irfan, who are focused on using up-to-date techniques to improve patient quality of life. The broader Azura network treats a wide array of vascular conditions, including uterine fibroids, varicose veins, and varicoceles, positioning itself to serve the nearly one in five Americans affected by some form of vascular disease.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 206
- Open positions
- None listed
- Dealroom signal
- 26.7/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotechnology, Surgery, Non-Invasive medical devices and treatments, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Nov 2011 | $11M | $44M | Undisclosed | — |
Growth signals
Latest recorded traffic for Baton Rouge Vascular Access is 24K monthly website visits, up 33.3% over the last three months. Baton Rouge Vascular Access's team declined 14.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Baton Rouge Vascular Access in the Baton Rouge ecosystem
The Baton Rouge Vascular Access office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Baton Rouge Vascular Access on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Baton Rouge Vascular Access’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







